Brazil Medical Devices Market Report 2026: ANVISA Regulation, SUS Procurement, and Commercial Strategy Intelligence

The Brazilian medical devices market is estimated at USD 11–13 billion in 2026, making it the largest medical device market in Latin America. Brazil has the world's seventh-largest installed base of medical imaging equipment and a significant domestic manufacturing capability in segments including wound care, dental equipment, disposables, and hospital furniture. The market is split between SUS (public hospital procurement through state and municipal health secretariats, approximately 45%) and the private supplementary sector (hospital groups like Rede D'Or, UnitedHealth/Amil, and premium hospitals Einstein, Sírio-Libanês, accounting for 55%).

ANVISA (Agência Nacional de Vigilância Sanitária) regulates medical devices (Equipamentos e Materiais Médico-Hospitalares) in Brazil through a risk-based classification system. Devices are classified as Class I (lowest risk), Class II, Class III, and Class IV (highest risk). ANVISA registration is mandatory for all devices sold in Brazil — Class I requires only notification, while Class II–IV require full registration with technical dossier review. Registration timelines range from 3–12 months for Class I–II and up to 18–24 months for Class III–IV. ANVISA also oversees the Registro de Empresa de Serviço de Saúde (company registration) and Autorização de Funcionamento (AFE) for importers and distributors. Post-market surveillance includes mandatory adverse event reporting (Tecnovigilância) to ANVISA.

RDC n° 751/2022 (Resolução da Diretoria Colegiada 751/2022) is ANVISA's consolidated regulation governing the classification, registration, and post-market requirements for medical devices, replacing the older RDC 185/2001 framework. It sets out the four risk-based classes — Class I (low risk, e.g. surgical instruments, wheelchairs), Class II (medium risk, e.g. infusion pumps, diagnostic ultrasound), Class III (high risk, e.g. implantable orthopedic devices, ventilators), and Class IV (maximum risk, e.g. cardiac implants, heart valves) — and defines which dossier elements, including the technical file, clinical evaluation report, and ISO 14971 risk management file, are required at each level. RDC 751 also formalized the "notificação" pathway for Class I devices, letting manufacturers self-declare compliance rather than undergo full technical review, which meaningfully shortens time-to-market for lower-risk products. For Class III and IV devices, the regulation requires a locally accountable Responsável Técnico and, in most cases, evidence of Brazilian Good Manufacturing Practice compliance at the site of manufacture.

INMETRO (Instituto Nacional de Metrologia, Qualidade e Tecnologia) administers a compulsory certification program for electro-medical equipment that runs alongside, and separately from, ANVISA registration. Devices covered by INMETRO's conformity assessment requirements — including patient monitors, infusion pumps, defibrillators, X-ray systems, and other equipment connected to mains power or to patients — must be tested against the NBR IEC 60601 series of electrical safety and electromagnetic compatibility standards by an INMETRO-accredited certification body before they can be commercially distributed. INMETRO certification typically proceeds in parallel with the ANVISA registration process rather than after it, but manufacturers frequently underestimate the lead time needed to test physical units in an accredited Brazilian laboratory, which can add several months to a launch plan. Electromedical equipment that lacks valid INMETRO certification can be held at customs or excluded from SUS and private hospital tenders, so distributors treat INMETRO compliance as a hard gate rather than a formality.

Brazilian Good Manufacturing Practice certification, known locally as Certificado de Boas Práticas de Fabricação or BGMP/BPF, is ANVISA's attestation that a manufacturing site meets Brazilian quality-system requirements, and it is generally required before Class III and Class IV devices can be registered. ANVISA can grant BGMP status either through a direct on-site inspection of the facility, including plants located outside Brazil, or, for certain jurisdictions, by relying on inspection reports issued by recognized foreign regulators or PIC/S-aligned authorities, which can reduce the need for a duplicate audit. Because scheduling an ANVISA inspection of a foreign plant can take many months, manufacturers targeting Brazil's Class III/IV segment typically start the BGMP process well before filing their technical dossier so it does not become the critical-path bottleneck. Distributors and importers of record must separately hold their own Autorização de Funcionamento (AFE) from ANVISA, confirming they are licensed to import, store, and distribute regulated medical devices within Brazil.

SUS (Sistema Único de Saúde) public hospital procurement follows Lei n° 8.666/93 and the newer Lei de Licitações (Lei n° 14.133/2021), requiring competitive public tender (licitação) processes for device purchases. Pregão eletrônico (electronic reverse auction) is the most common procurement modality. Federal hospitals (Empresa Brasileira de Serviços Hospitalares, EBSERH network of 40+ university hospitals) and state and municipal health secretariats each manage independent procurement. The PROQUALIS program and OPAS/PAHO frameworks provide guidance on quality standards for SUS device procurement. CONASS (National Council of State Health Secretariats) and CONASEMS coordinate procurement across the federated system. Import taxes (II, IPI, PIS, COFINS) can add 25–60% to device costs for imported products, creating a competitive advantage for locally manufactured devices.

The fastest-growing Brazilian medical device segments are: continuous glucose monitoring (CGM reimbursement through ANS mandates and SUS pilot programs; rapid prescription growth); diagnostics and molecular testing (post-COVID investment in laboratory and point-of-care diagnostic infrastructure); robotic surgery (Rede D'Or, Hospital Albert Einstein, and Hospital Sírio-Libanês expanding robotic surgical programs); oncology devices (infusion pumps, radiotherapy equipment, linear accelerators — driven by SUS cancer network and premium private oncology centres); and minimally invasive cardiovascular devices (TAVR, LAAO — in premium private hospitals at international price points). Dental and implantology devices remain a major domestic manufacturing segment.

Key challenges in the Brazil medical device market include: (1) ANVISA registration complexity and timeline — Class III/IV dossiers require complete technical documentation in Portuguese and can take 18–24 months; (2) Import tax burden — II + IPI + PIS + COFINS taxes can add 40–60% to device costs for fully imported products, disadvantaging international manufacturers versus local assembly; (3) SUS procurement delays — public tender processes can extend purchase cycles to 12–18 months from contract award to delivery; (4) Currency volatility — BRL/USD exchange rate fluctuations significantly impact pricing competitiveness; (5) Two-speed market — premium private hospitals (premium-priced, fast adoption) versus SUS public hospitals (price-sensitive, slow procurement) require fundamentally different commercial strategies.

BioNixus delivers medical device market research in Brazil: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports Brazil-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative Brazil versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.